Health · Pharma & Biotech · 3 hrs ago
FDA Approves Pimicotinib for Some Patients With TGCT
The FDA approved pimicotinib, an oral medicine sold as Pimjetmi, for selected patients with tenosynovial giant cell tumor, or TGCT.
TGCT is a rare, benign soft-tissue tumor.
The approval covers people whose TGCT causes symptoms and who face a high risk from surgery.
Pimicotinib is a small-molecule inhibitor.
The approval gives these patients another treatment option.
The approval applies to selected patients with symptomatic TGCT and high surgical risk.
The FDA approved pimicotinib, sold as Pimjetmi, for selected patients with tenosynovial giant cell tumor.
The approval covers patients with symptomatic TGCT who face high surgical risk.
Pimicotinib is an oral, selective small-molecule inhibitor.
TGCT is described as a rare, benign soft-tissue tumor.
- Who
- The FDA approved pimicotinib for selected patients with TGCT.
- What
- The agency approved the drug for symptomatic TGCT in patients with high surgical risk.
- When
- Not stated
- Where
- Not stated
- Why
- It is for selected patients with symptomatic TGCT who face high surgical risk.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Drug
- Pimicotinib
- Brand name
- Pimjetmi
- Treatment type
- Oral, selective small-molecule inhibitor
- Condition
- Tenosynovial giant cell tumor (TGCT)
- Eligible patients
- Those with symptomatic TGCT and high surgical risk